Ollie's Bargain Outlet Stock (NASDAQ: OLLI)

Ollie's Bargain Outlet (NASDAQ:OLLI) Stock

Ollie's Bargain Outlet

Ollie's Bargain Outlet Holdings Inc is a retailer of brand-name merchandise at drastically reduced prices. It offers customers a selection of brand-name products, including housewares, food, books and stationery, bed and bath, floor coverings, toys, and hardware. It operates stores across the Eastern half of the United States. Its differentiated go-to-market plan is characterized by a fun, and engaging treasure hunt shopping experience, compelling customer value proposition, and witty, humorous in-store signage and advertising campaigns. These attributes have driven rapid growth and consistent store performance for the company.

Ollie's Bargain Outlet Holdings, Inc. - Common Stock

Ollie's Bargain Outlet Holdings Inc

Earnings

News

Obsidian Energy Q4 EPS $0.96 Down From $1.33 YoY

B of A Securities analyst Eli Abboud initiates coverage on BGC Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGC#NASDAQ">BGC</a>) with a Buy rating and announces Price Target of $16.

Price Target

Initiation

Analyst Ratings

B of A Securities Initiates Coverage On BGC Group with Buy Rating, Announces Price Target of $16

<ul>
<li>Kiniksa plans to initiate a Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis in mid-2025.</li>
<li>KPL-387 Phase 1 single ascending dose data support potential monthly dosing.</li>
<li>Kiniksa continues to focus development on diseases with unmet needs, prioritizing cardiovascular indications.</li>
<li>Kiniksa to discontinue abiprubart development in Sjögren's Disease</li>
</ul>

Biotech

Health Care

General

KNSA

Kiniksa Pharmaceuticals Announced The Development Program For KPL-387 In Recurrent Pericarditis And Provided An Update On Its Corporate Strategy

B of A Securities analyst Tim Anderson initiates coverage on Metsera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSR#NASDAQ">MTSR</a>) with a Buy rating and announces Price Target of $38.

MTSR

B of A Securities Initiates Coverage On Metsera with Buy Rating, Announces Price Target of $38

Guidance

PYPL

PayPal Sees FY27 Adj EPS Growth In Low teens

On Tuesday, Home Depot Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>) stock is trading higher in a volatile session after the home improvement retailer reported its <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43935026/the-home-depot-announces-fourth-quarter-and-fiscal-2024-results-increases-quarterly-dividend-by-2-" rel="noreferrer noopener">fourth-quarter 2024 results and provided its 2025 outlook</a>.
HD reported fourth-quarter sales growth of 14.1% year-over-year to $39.70 billion, beating the <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">consensus estimate of $39.14 billion</a>. Adjusted EPS was $3.13 (+9.4% year over year), beating the consensus of $3.00.&nbsp;
Customer transactions for the quarter rose 7.6%. Comparable sales increased 0.8%, and comparable sales in the U.S. rose 1.3%.
Related: <a target="_blank" href="https://www.benzinga.com/trading-ideas/previews/25/02/43922935/home-depot-q4-earnings-preview-could-slowing-new-home-sales-higher-mortgage-rates-help-stock" rel="noreferrer noopener">Home Depot Q4 Earnings Preview: Could &#8216;Slowing New Home Sales And Higher Mortgage Rates&#8217; Help The Stock?</a>
Margins: Gross profit rose 13.3% YoY to $13.03 billion, with a margin of 32.8%, down 25 bps YoY. The operating margin was 11.3%, down 60 bps YoY, and operating income for the quarter rose 8.5% to $4.495 billion. The adjusted operating margin slipped to 11.7% from 12.1% YoY.
Operating expenses increased 15.9% year over year to $8.539 billion.
The average ticket in the fourth quarter was $89.11, a 0.3% increase, and sales per retail square foot increased 1.2% to $556.90.
As of February 2, the company held $1.659 billion in cash and equivalents. It generated an operating cash flow of $19.810 billion for fiscal 2024, compared to $21.172 billion a year ago.
At the end of the quarter, HD operated 2,347 retail stores and over 780 branches across the U.S., Canada, and Mexico.
Dividend: Home Depot announced a 2.2% increase in its quarterly dividend to $2.30 per share, totaling an annual dividend of $9.20 per share. The dividend is payable on March 27, 2025, to shareholders of record as of March 13, 2025.
2025 Outlook: Home Depot forecasts total sales growth of 2% year-over-year, reaching $163.98 billion, slightly below the consensus of $164.17 billion.
Comparable sales are expected to rise approximately 1%, with an adjusted operating margin of around 13.4%.
The company projects adjusted EPS to decline by about 2%, from $15.24 to $14.94, falling short of the $15.57 consensus estimate.
Price Action: HD shares are trading higher by 1.15% at $386.80 premarket on the last check Tuesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/43166746/home-depot-likely-to-outcomp-lowes-in-q4-analyst-says-as-home-improvement-battle-heads-toward-earnings" target="_blank" rel="noreferrer noopener">Home Depot &#8216;Likely To Outcomp&#8217; Lowe&#8217;s In Q4, Analyst Says As Home Improvement Battle Heads Toward Earnings</a></li>
</ul>
Photo: Sockagphoto via Shutterstock

Dividends

Trading Ideas

Home Depot Lifts Annual Dividend After Strong Q4, But Soft 2025 Outlook Weighs On Stock

PayPal Reaffirms FY25 Adj EPS Growth Of 6% - 10%

WIIM

PayPal shares are trading higher after the company issued outlook ahead of its Investor Day event.

Janney Montgomery Scott analyst Thomas Meric initiates coverage on Solaris Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEI#NYSE">SEI</a>) with a Buy rating and announces Price Target of $57.

Janney Montgomery Scott Initiates Coverage On Solaris Energy with Buy Rating, Announces Price Target of $57

Financial Guidance
<ul>
<li>Kiniksa expects 2025 ARCALYST net product revenue of between $560 million and $580 million.</li>
<li>Kiniksa expects its current operating plan to remain cash flow positive on an annual basis.</li>
</ul>

Kiniksa Expects 2025 Arcalyst Net Product Revenue Of Between $560M-$580M

Cipher Mining (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIFR#NASDAQ">CIFR</a>) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $(0.05) by 380 percent. This is a 27.27 percent increase over earnings of $0.11 per share from the same period last year. The company reported quarterly sales of $42.22 million which missed the analyst consensus estimate of $42.69 million by 1.10 percent. This is a 66.71 percent decrease over sales of $126.84 million the same period last year.

Earnings Beats

Earnings Misses

CIFR

Cipher Mining Q4 Adj EPS $0.14 Beats $(0.05) Estimate, Sales $42.22M Miss $42.69M Estimate

Kiniksa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KNSA#NASDAQ">KNSA</a>) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $0.04 by 400 percent. This is a 134.29 percent decrease over earnings of $0.35 per share from the same period last year. The company reported quarterly sales of $122.54 million which missed the analyst consensus estimate of $123.38 million by 0.68 percent. This is a 46.93 percent increase over sales of $83.39 million the same period last year.

Kiniksa Pharmaceuticals Q4 2024 GAAP EPS $(0.12) May Not Be Comparable To $0.04 Estimate, Sales $122.54M Miss $123.38M Estimate

ARWR

Arrowhead Pharmaceuticals Presented Preclinical Data On ARO-ALK7 At Keystone Symposia on Obesity and Adipose Tissue

Canaccord Genuity analyst David Hynes maintains Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) with a Buy and raises the price target from $190 to $220.

SNOW

Canaccord Genuity Maintains Buy on Snowflake, Raises Price Target to $220

Cipher Mining Q4 2024 Adj EPS $0.14 Beats $(0.05) Estimate, Sales $42.22M Miss $42.69M Estimate

LVTX

LAVA Initiates Process To Review Strategic Options

Harmony Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRMY#NASDAQ">HRMY</a>) reported quarterly earnings of $1.08 per share which beat the analyst consensus estimate of $0.74 by 45.95 percent. This is a 47.95 percent increase over earnings of $0.73 per share from the same period last year. The company reported quarterly sales of $201.27 million which beat the analyst consensus estimate of $201.25 million by 0.01 percent. This is a 19.51 percent increase over sales of $168.41 million the same period last year.

HRMY

Harmony Biosciences Q4 Adj $1.08 Beats $0.74 Estimate, Sales $201.27M Beat $201.25M Estimate

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4369226-1&amp;h=785781941&amp;u=http%3A%2F%2Fwww.trevitherapeutics.com%2F&amp;a=Trevi+Therapeutics%2C+Inc.">Trevi Therapeutics, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVI#NASDAQ">TRVI</a>), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio&#x2122; (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that it has completed enrollment in its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF. Topline results continue to be expected in the first half of 2025.

TRVI

Trevi Therapeutics Completes Enrollment for Phase 2b Trial of Haduvio in Chronic Cough

PSEG Sees FY25 Non-GAAP Operating Earnings $3.94-$4.06 vs $4.01 Est.

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates UroGen Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URGN#NASDAQ">URGN</a>) with a Buy and maintains $64 price target.

Reiteration

URGN

HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $64 Price Target

Press Releases

OLLIE'S CELEBRATES GRAND OPENING AND RIBBON CUTTING AT NEW ILLINOIS DISTRIBUTION CENTER

Ollie's Bargain Outlet Holdings, Inc. Reports Second Quarter Fiscal 2024 Financial Results

OLLIE'S CELEBRATES 10 GRAND OPENINGS IN TEXAS

Ollie's Bargain Outlet Acquires Former Big Lots Stores

Ollie's Bargain Outlet Acquires Additional Former Big Lots Stores

Ollie's Bargain Outlet Holdings, Inc. Announces Third Quarter Fiscal 2024 Release Date and Conference Call Information

Ollie's Bargain Outlet Holdings, Inc. Reports Third Quarter Fiscal 2024 Financial Results

OLLIE'S RAISES OVER $1.1 MILLION FOR MARINE TOYS FOR TOTS PROGRAM

Management

Ollie's Bargain Outlet Announces the Appointment of Eric van der Valk to President & Chief Executive Officer, Completing Leadership Succession Plan

OLLIE'S CELEBRATES THE  GRAND OPENING OF FOUR WISCONSIN STORES

OLLI

Amazon.com

Alibaba Group Holding Limited American Depositary Shares each representing eight Ordinary share

Alibaba Gr Hldgs

Baozun

Coupang

Dillard's

1stdibs.com

eBay

Etsy

Global E Online

Groupon

D-Market Electronic Services & Trading - American Depositary Shares

D-MARKET Electronic

Hour Loop

JD.com, Inc. - American Depositary Shares

JD.com

Jumia Technologies AG American Depositary Shares, each representing two Ordinary Shares

Jumia Technologies

Nordstrom

Kohl's

ContextLogic

Macy's

MercadoLibre

MINISO Group Holding Limited American Depositary Shares, each representing four Ordinary Shares

MINISO Group Holding

PDD Holdings Inc. - American Depositary Shares

PDD Holdings

QVC Group

Savers Value Village

Vipshop Holdings Limited American Depositary Shares, each representing two ordinary shares

Comments

Ollie's Bargain Outlet

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL